Advanced Enzyme Technologies Limited — PPTs, 13-05-2025: Investor Presentation

1. Financial Highlights:

Consolidated revenue grew 2% YoY to ₹636.9 Cr in FY25, supported by moderate gains in human and animal nutrition. EBITDA fell 5% to ₹194.4 Cr with margins narrowing to 31%. PAT declined 2% to ₹134 Cr, reflecting cost pressures. Q4 revenue rose 6% YoY to ₹167.2 Cr, but EBITDA and PAT dropped 18% and 11%, respectively, with sequential declines in profits. The balance sheet remains robust with net worth at ₹1,421 Cr, low net debt-to-equity of 0.10x, and stable ROE/ROCE near 11-13%.

2. Strategic Initiatives & Growth Drivers:

The company is boosting its product pipeline in enzymes, probiotics, bio-catalysis, and baking solutions, increasing R&D spend, especially in genetic engineering. Geographic expansion targets the USA, MENA, and Asia through distributor networks and enhanced sales teams. Early-stage bio-catalysis trials and baking industry products signal diversification efforts.

3. Business Developments:

No new acquisitions, but continued integration of JC Biotech and SciTech Specialities. Specialty launches in probiotics and nutrition are progressing, supported by positive trials and regulatory filings aimed at future commercialization.

4. Market Position & Competitive Advantage:

With 68+ proprietary enzymes/probiotics, nine manufacturing sites, and presence in 45+ countries, the company holds a global leadership position. Its integrated R&D-to-marketing model, cost-efficient scale, and strong patent portfolio provide a defensible moat and high entry barriers in enzyme markets.

5. Investor Implications:

Modest revenue growth alongside margin pressure indicates manageable near-term obstacles. The strong financial position and targeted investments in probiotics and bio-catalysis support positive growth potential. Execution risks lie in commercializing new products and scaling geographically. Watch for profitability recovery and traction in advanced offerings to validate strategy.